Scans of the chest to predict how scleroderma lung disease may progress
Studies chest scan measures to see if they predict lung disease worsening in scleroderma.
Plain-language title generated from the registry record
Registry title: Chest CT Biomarkers as Prognostic Predictors in SSc-ILD
Key facts
- Where
- Ancona, Sassari, and Siena, ItalySee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 99 years old?
Source: NCT06472362, who can take part
Where in Italy
- Marche Polytechnic UniversityAncona, ItalyNo longer taking part
- Sassari UniversitySassari, ItalyNo longer taking part
- Siena University HospitalSiena, ItalyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Royal Brompton & Harefield NHS Foundation Trust
- Trial code
- NCT06472362
- Record updated
- 11 September 2025
- Original description
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.Read full original descriptionShow less
Deep-learning Derived Chest Computed Tomography (CT) Biomarkers as Prognostic Predictors in Systemic Sclerosis Associated Interstitial Lung Disease (SSc-ILD)
The goal of this retrospective observational study is to investigate whether novel imaging biomarkers of airways, vessels, and overall extent of fibrosis at baseline predict ILD progression, vasculopathy development, and survival in SSc-ILD.
Inclusion: diagnosed with SSc; ≥18 years old; HRCT between 01/01/1990 and 31/12/2019.
Exclusion: <18 years old; Patients who do not have SSc; lack of availability of HRCT imaging data.